menu
    • menu
    [{"orgOrder":0,"company":"Luminera","sponsor":"Innovative Luminera","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Luminera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luminera \/ Innovative Luminera","highestDevelopmentStatusID":"15","companyTruncated":"Luminera \/ Innovative Luminera"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"University of Seville","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Epithelial cell adhesion molecule","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of Seville","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"University of Seville \/ Alcon Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Seville \/ Alcon Inc"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2024","type":"Acquisition","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"||Epithelial cell adhesion molecule","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"University of Campinas, Brazil","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BRAZIL","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Epithelial cell adhesion molecule","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"University of Campinas, Brazil","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Campinas, Brazil \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Campinas, Brazil \/ Merck & Co"},{"orgOrder":0,"company":"DeNova Research","sponsor":"Merz Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Hydroxylapatite","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"DeNova Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"DeNova Research \/ Merz Aesthetics","highestDevelopmentStatusID":"11","companyTruncated":"DeNova Research \/ Merz Aesthetics"},{"orgOrder":0,"company":"Main Line Center for Laser Surgery","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Main Line Center for Laser Surgery","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Main Line Center for Laser Surgery \/ Merz Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Main Line Center for Laser Surgery \/ Merz Therapeutics"},{"orgOrder":0,"company":"Dubai Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.A.E","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Dubai Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Dubai Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dubai Health \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Milton M. Hom","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2010","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Epithelial cell adhesion molecule","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Milton M. Hom","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Milton M. Hom"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Kalpna Kay Durairaj","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Hydroxylapatite","graph1":"Dermatology","graph2":"Phase I","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merz Pharma \/ Kalpna Kay Durairaj","highestDevelopmentStatusID":"6","companyTruncated":"Merz Pharma \/ Kalpna Kay Durairaj"}]

    Find Clinical Drug Pipeline Developments & Deals for Ossopan

    Menu

    Ossopan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Allergan Aesthetics

                            U.S.A
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allergan Aesthetics Brings Data, Innovation & Industry Expertise to the 2022 Aesthetic and Anti-aging Medicine...

                            Details : Allergan Aesthetics looks to further develop the Hybrid Injectables category by introducing its first dual-effect product, which combines the two active ingredients - hyaluronic acid, a well-known ingredient found in facial fillers and calcium hydroxyapa...

                            Product Name : Juvederm Volux XC

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 29, 2022

                            Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Milton M. Hom

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tear Osmolarity Over Time With Artificial Tears

                            Details : HYDROXYPROPYLMETHYLCELLULOSE is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            October 25, 2010

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Milton M. Hom

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dubai Health

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Dubai Health

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hydroxyapatite vs Fluoride Toothpaste for MIH Remineralization

                            Details : Hydroxyapatite is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Molar Incisor Hypomineralisation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 16, 2025

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of Seville

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Seville

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Alcon Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immediate Effects of Lipid-Based and Non-Lipid Artificial Tears on Corneal Aberrations

                            Details : HYDROXYPROPYLMETHYLCELLULOSE is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            January 20, 2025

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Alcon Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : OcuMension Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins

                            Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.

                            Product Name : Tears Naturale Forte

                            Product Type : Carbohydrate

                            Upfront Cash : Undisclosed

                            August 12, 2024

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : OcuMension Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Merz Pharma

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Kalpna Kay Durairaj

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Calcium Hydroxylapatite on Cellulite Dimples in the Buttocks

                            Details : Calcium Hydroxyapatite is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cellulite.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 01, 2023

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Kalpna Kay Durairaj

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Main Line Center for Laser Surgery

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Main Line Center for Laser Surgery

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Merz Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational

                            Details : Calcium Hydroxylapatite is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 10, 2021

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Merz Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Luminera

                            Israel arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Luminera

                            Israel arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Innovative Luminera

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business

                            Details : Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® collection of fillers.

                            Product Name : HArmonyCa

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 07, 2020

                            Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Innovative Luminera

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of Campinas, Brazil

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Campinas, Brazil

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients

                            Details : HYDROXYPROPYLMETHYLCELLULOSE is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            January 20, 2011

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            DeNova Research

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            DeNova Research

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Sponsor : Merz Aesthetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Injectable Filler for Cheek Flattening

                            Details : Calcium Hydroxyapatite is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malar Deficiency.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 21, 2010

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Sponsor : Merz Aesthetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth